source
- ADARx upsizes Nasdaq IPO to $446M as City Therapeutics eyes public listingADARx Pharmaceuticals, a San Diego-based RNA biotech, completed a Nasdaq initial public offering this morning, selling 26.3 million shares at $17 each. The offering generated gross proceeds of abo…
- Lundbeck plans US headquarters move to Boston to boost neuroscience R&DLundbeck, a Danish pharmaceutical company focused on neuroscience, announced it will relocate its U.S. operations to Boston. The move is part of a broader strategy to concentrate R&D on increasing…